Search research articles
Contact Us
Filters
Showing results (31-40 of 41) with videos related to
Page
of 5
Sort By:
Cancers
|
July 24, 2021
Development of a Metastatic Uveal Melanoma Prognostic Score (MUMPS) for Use in Patients Receiving Immune Checkpoint Inhibitors
Deirdre Kelly, April A N Rose, Thiago Pimentel Muniz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 16, 2018
Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas
Matthew Dankner, Mathieu Lajoie, Dan Moldoveanu, et al.
JCO Precision Oncology
|
January 27, 2025
Clinical Activity of Mitogen-Activated Protein Kinase Inhibitors in Patients With MAP2K1 (MEK1)-Mutated Metastatic Cancers
Matthew Dankner, Emmanuelle Rousselle, Sarah Petrecca, et al.
Science Advances
|
September 7, 2022
The spindle assembly checkpoint is a therapeutic vulnerability of CDK4/6 inhibitor-resistant ER<sup>+</sup> breast cancer with mitotic aberrations
Isabel Soria-Bretones, Kelsie L Thu, Jennifer Silvester, et al.
Breast (Edinburgh, Scotland)
|
May 8, 2023
Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases
Anna-Maria Lazaratos, Sarah M Maritan, Andrea Quaiattini, et al.
Molecular Cancer Therapeutics
|
February 1, 2023
Inhibition of the MNK1/2-eIF4E Axis Augments Palbociclib-Mediated Antitumor Activity in Melanoma and Breast Cancer
Sathyen A Prabhu, Omar Moussa, Christophe Gonçalves, et al.
Oncogene
|
February 3, 2022
HSP90 inhibitors induce GPNMB cell-surface expression by modulating lysosomal positioning and sensitize breast cancer cells to glembatumumab vedotin
Marco Biondini, Alex Kiepas, Leeanna El-Houjeiri, et al.
JCO Precision Oncology
|
August 17, 2022
Clinical Activity of Mitogen-Activated Protein Kinase-Targeted Therapies in Patients With Non-V600 BRAF-Mutant Tumors
Matthew Dankner, Yifan Wang, Rouhi Fazelzad, et al.
Nature Communications
|
January 3, 2026
Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trial
April A N Rose, Jennifer Maxwell, Emmanuelle Rousselle, et al.
Journal for Immunotherapy of Cancer
|
January 20, 2021
Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition
Aljosja Rogiers, Ines Pires da Silva, Chiara Tentori, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 41) with videos related to
Sort By:
Page
of 5
Cancers
|
July 24, 2021
Development of a Metastatic Uveal Melanoma Prognostic Score (MUMPS) for Use in Patients Receiving Immune Checkpoint Inhibitors
Deirdre Kelly, April A N Rose, Thiago Pimentel Muniz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 16, 2018
Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas
Matthew Dankner, Mathieu Lajoie, Dan Moldoveanu, et al.
JCO Precision Oncology
|
January 27, 2025
Clinical Activity of Mitogen-Activated Protein Kinase Inhibitors in Patients With MAP2K1 (MEK1)-Mutated Metastatic Cancers
Matthew Dankner, Emmanuelle Rousselle, Sarah Petrecca, et al.
Science Advances
|
September 7, 2022
The spindle assembly checkpoint is a therapeutic vulnerability of CDK4/6 inhibitor-resistant ER<sup>+</sup> breast cancer with mitotic aberrations
Isabel Soria-Bretones, Kelsie L Thu, Jennifer Silvester, et al.
Breast (Edinburgh, Scotland)
|
May 8, 2023
Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases
Anna-Maria Lazaratos, Sarah M Maritan, Andrea Quaiattini, et al.
Molecular Cancer Therapeutics
|
February 1, 2023
Inhibition of the MNK1/2-eIF4E Axis Augments Palbociclib-Mediated Antitumor Activity in Melanoma and Breast Cancer
Sathyen A Prabhu, Omar Moussa, Christophe Gonçalves, et al.
Oncogene
|
February 3, 2022
HSP90 inhibitors induce GPNMB cell-surface expression by modulating lysosomal positioning and sensitize breast cancer cells to glembatumumab vedotin
Marco Biondini, Alex Kiepas, Leeanna El-Houjeiri, et al.
JCO Precision Oncology
|
August 17, 2022
Clinical Activity of Mitogen-Activated Protein Kinase-Targeted Therapies in Patients With Non-V600 BRAF-Mutant Tumors
Matthew Dankner, Yifan Wang, Rouhi Fazelzad, et al.
Nature Communications
|
January 3, 2026
Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trial
April A N Rose, Jennifer Maxwell, Emmanuelle Rousselle, et al.
Journal for Immunotherapy of Cancer
|
January 20, 2021
Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition
Aljosja Rogiers, Ines Pires da Silva, Chiara Tentori, et al.
Page
of 5